Managing aromatase inhibitor-associated bone loss in breast cancer

Keyphrases

• 5-year Survival 33%
• Adjuvant Therapy 66%
• Adverse Effects 33%
• Aromatase Inhibitor-associated Bone Loss 100%
• Aromatase Inhibitors 33%
• Bisphosphonates 33%
• Bone Loss 100%
• Bone Metabolism 33%
• Bone Metastasis 33%
• Breast Cancer 100%
• Death Rate 33%
• Early Breast Cancer 33%
• Europe 33%
• Long-term Treatment 33%
• Menopause 33%
• Osteolytic Bone Lesions 33%
• US FDA 33%
• Zoledronic Acid 33%

Medicine and Dentistry

• Adjuvant Endocrine Therapy 20%
• Adjuvant Therapy 20%
• Adverse Effect 20%
• Aromatase Inhibitor 100%
• Bisphosphonate 20%
• Bone Lesion 20%
• Bone Metastasis 20%
• Breast Cancer 100%
• Cancer Adjuvant Therapy 20%
• Mortality Rate 20%
• Osteolysis 100%
• Survival Rate 20%
• Zoledronic Acid 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Aromatase Inhibitor 100%
• Bisphosphonic Acid Derivative 25%
• Bone Lesion 25%
• Bone Metastasis 25%
• Breast Cancer 100%
• Endocrine Therapy 25%
• Malignant Neoplasm 25%
• Mortality Rate 25%
• Survival Rate 25%
• Zoledronic Acid 25%